A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Public ClinicalTrials.gov record NCT01321346. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is for patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Hodgkin's Disease (HD) or Non-Hodgkin's Lymphoma (NHL). Panobinostat is a new drug that is considered investigational because it has not been approved in the United States by the Food and Drug Administration (FDA), or in any other country. Panobinostat is a histone deacetylase inhibitor (HDACi) and interferes with gene expression found in cells causing them to stop growing or die. Panobinostat has been used in several hundred adults who had leukemia, HD, NHL and other solid tumors. Panobinostat has not been given to children. This is a phase I study. In a phase I study, drugs are tested to the highest dose that can be safely given. Drugs are given at gradually increasing dosages until there are unacceptable side effects. The goal of the Phase I study is to find out the dose of panobinostat that can be safely given to children with relapsed ALL, AML, HD and NHL.
Study identification
- NCT ID
- NCT01321346
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 8 Years to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2011
- Primary completion
- Sep 30, 2015
- Completion
- Not listed
- Last update posted
- Nov 23, 2015
Started 2011
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Childrens Hospital Los Angeles | Los Angeles | California | 90027 | — |
| UCSF School of Medicine | San Francisco | California | 94143-0106 | — |
| Children's National Medical Center | Washington D.C. | District of Columbia | — | — |
| University of Miami Cancer Center | Miami | Florida | 33136 | — |
| Children's Healthcare of Atlanta, Emory University | Atlanta | Georgia | — | — |
| Lurie Children's Hospital | Chicago | Illinois | — | — |
| Dana Farber | Boston | Massachusetts | — | — |
| C.S. Mott Children's Hospital | Ann Arbor | Michigan | 48109-0914 | — |
| Childrens Hospital & Clinics of Minnesota | Minneapolis | Minnesota | 55404-4597 | — |
| New York University Medical Center | New York | New York | 10016 | — |
| Children's Hospital New York-Presbyterian | New York | New York | 10032 | — |
| Levine Children's Hospital at Carolinas Medical Center | Charlotte | North Carolina | 28203 | — |
| Rainbow Babies | Cleveland | Ohio | — | — |
| Nationwide Childrens Hospital | Columbus | Ohio | — | — |
| Oregon Health and Science University | Portland | Oregon | — | — |
| St. Jude | Memphis | Tennessee | 38105-3678 | — |
| Vanderbilt Children's Hospital | Nashville | Tennessee | — | — |
| Primary Children's | Salt Lake City | Utah | — | — |
| Seattle Children's Hospital | Seattle | Washington | 98105 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01321346, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 23, 2015 · Synced Sep 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01321346 live on ClinicalTrials.gov.